GBT2104-131 A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease (SCD) Experiencing Vaso-occlusive Crisis (VOCs)

Administered By

Awarded By

Contributors

Start/End

  • June 4, 2021 - May 31, 2024